Last 39 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | 0.91 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.00 | — | — | — | 149.05 | 7.35 | 7.76 | 6.29 | — | 3.90 | 2.45 | 3.43 | 6.57 | 12.34 | 16.59 | 23.78 | 29.21 | 26.43 | 38.20 | 27.37 | 149.37 |
| — | — | — | — | — | +88.6% | +216.9% | +83.3% | — | -68.4% | -85.2% | -85.6% | -77.5% | -53.3% | -56.6% | -13.1% | -80.4% | -86.6% | -81.7% | -83.9% | +183.7% | |
| P/B Ratio | 0.00 | — | — | 13.85 | 13.81 | 3.05 | 1.20 | 0.70 | 0.78 | 0.47 | 1.98 | 1.20 | 2.41 | 2.65 | 2.64 | 3.06 | 7.35 | 8.81 | 7.81 | 3.40 | 3.83 |
| — | — | — | +1888.8% | +1670.7% | +548.7% | -39.4% | -41.8% | -67.6% | -82.3% | -24.8% | -61.0% | -67.3% | -69.9% | -66.2% | -10.0% | +91.9% | +89.1% | +126.4% | -29.4% | +60.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.3% | — | — | — | 27.7% | 83.6% | 77.0% | 76.2% | 114.1% | 81.4% | 88.4% | 86.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | -75.7% | +2.7% | -13.0% | -11.8% | +14.1% | -18.6% | -11.6% | -13.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -1298.2% | — | — | — | -6996.1% | -920.7% | -1200.1% | -1124.3% | 658.4% | -1014.0% | -538.1% | -487.5% | -325.9% | -472.4% | -506.5% | -433.8% | -512.7% | -496.3% | -525.1% | -728.8% | -3970.5% |
| — | — | — | — | -1162.5% | +9.2% | -123.0% | -130.6% | +302.1% | -114.7% | -6.2% | -12.4% | +36.4% | +4.8% | +3.6% | +40.5% | +87.1% | +86.4% | +88.0% | +80.5% | -90.6% | |
| Net Margin | -1656.3% | — | — | — | -16679.8% | -1067.1% | -1279.8% | -505.2% | -504.4% | -541.0% | -560.8% | -432.4% | -305.2% | -456.9% | -435.7% | -294.8% | -528.7% | -509.0% | -539.4% | -724.1% | -3883.7% |
| — | — | — | — | -3206.9% | -97.2% | -128.2% | -16.8% | -65.3% | -18.4% | -28.7% | -46.7% | +42.3% | +10.3% | +19.2% | +59.3% | +86.4% | +85.6% | +87.2% | +80.0% | -92.3% |
| Metric | TTM | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -227.9% | — | -535.9% | -23.4% | -243.1% | -73.3% | -40.3% | -12.7% | 21.5% | -26.3% | -75.1% | -32.0% | -24.9% | -22.1% | -16.1% | -11.8% | -44.1% | -36.0% | -24.8% | -22.1% | -22.7% |
| — | — | -1230.3% | -83.7% | -1232.6% | -178.9% | +46.3% | +60.2% | +186.2% | -19.2% | -367.1% | -170.0% | +43.6% | +38.7% | +35.1% | +46.5% | -94.4% | -87.6% | -11.9% | +4.2% | -9.2% | |
| ROA | -79.8% | -6.7% | -19.3% | -2.4% | -40.8% | -24.4% | -18.8% | -6.6% | 10.4% | -10.2% | -25.3% | -14.1% | -12.2% | -11.8% | -9.1% | -6.0% | -17.4% | -13.9% | -11.1% | -11.1% | -13.4% |
| — | +72.7% | -2.9% | +63.1% | -491.1% | -138.3% | +25.8% | +53.0% | +185.6% | +13.0% | -178.0% | -135.0% | +29.9% | +15.0% | +18.2% | +45.7% | -29.5% | -3.5% | +31.3% | +34.4% | +15.3% | |
| ROIC | — | — | — | — | — | -552.1% | -58.0% | -54.7% | -118.8% | -98.3% | -51.3% | -33.8% | -33.4% | -44.4% | -137.7% | — | — | -7538.5% | -394.3% | -37.6% | -20.7% |
| — | — | — | — | — | -461.9% | -13.1% | -61.7% | -255.8% | -121.2% | +62.7% | — | — | +99.4% | +65.1% | — | — | -27377.8% | -860.3% | -8.5% | +40.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.73 | — | — | 4.10 | 3.73 | 1.78 | 0.86 | 0.61 | 0.50 | 0.50 | 2.15 | 1.07 | 0.76 | 0.62 | 0.51 | 0.44 | 0.73 | 1.02 | 0.75 | 0.60 | 0.33 |
| — | — | — | +569.9% | +648.6% | +259.9% | -60.1% | -42.7% | -34.9% | -19.8% | +325.0% | +142.5% | +4.6% | -39.4% | -33.0% | -26.6% | +123.4% | +352.5% | +348.7% | +1204.0% | +82971.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.95 | 2.25 | 3.46 | 3.01 | 3.95 | 4.31 | 5.38 | 7.37 | 6.87 | 6.57 | 2.36 | 4.22 | 4.33 | 5.13 | 6.74 | 8.28 | 6.24 | 3.51 | 4.85 | 6.35 | 4.87 |
| — | -47.8% | -35.6% | -59.2% | -42.5% | -34.3% | +127.7% | +74.7% | +58.4% | +28.0% | -65.0% | -49.0% | -30.5% | +46.0% | +39.1% | +30.5% | +28.1% | -28.6% | -40.2% | +22.2% | -6.5% | |
| Quick Ratio | 3.95 | 2.25 | 3.46 | 3.01 | 3.95 | 4.31 | 5.38 | 7.37 | 6.87 | 6.57 | 2.36 | 4.22 | 4.33 | 5.13 | 6.74 | 8.28 | 6.24 | 3.51 | 4.85 | 6.35 | 4.86 |
| — | -47.8% | -35.6% | -59.2% | -42.5% | -34.3% | +127.7% | +74.7% | +58.4% | +28.0% | -65.0% | -49.0% | -30.5% | +46.0% | +39.1% | +30.5% | +28.4% | -28.6% | -40.2% | +22.2% | -6.8% | |
| Interest Coverage | -31.10 | -3.88 | -15.88 | -1.84 | -47.45 | -29.81 | -27.37 | -18.55 | -3.24 | -27.78 | -34.15 | -24.76 | -23.15 | -25.45 | -22.21 | -13.71 | — | -38.53 | -34.38 | -63.56 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 39 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SYRS stock.
Syros Pharmaceuticals, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Syros Pharmaceuticals, Inc.'s current operating margin is -1298.2%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Syros Pharmaceuticals, Inc.'s business trajectory between earnings reports.